HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.

@article{Leo2002HER2AA,
  title={HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.},
  author={Angelo Leo and David Gancberg and Denis P Larsimont and Minna Tanner and Tero Jarvinen and Ghizlane Rouas and Stella Dolci and J Leroy and Marianne Paesmans and Jorma Isola and Martine J. Piccart},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2002},
  volume={8 5},
  pages={1107-16}
}
PURPOSE The purpose of this study is to evaluate HER-2 and topoisomerase IIalpha (topo IIalpha) as candidates for predicting the activity of anthracyclines in the adjuvant treatment of breast cancer patients. EXPERIMENTAL DESIGN In this study, we evaluated HER-2 and topo IIalpha gene aberrations by fluorescence in situ hybridization in a series of 430 primary breast cancer samples. Samples came from node-positive breast cancer patients randomly treated either with one of two anthracycline… CONTINUE READING
107 Extracted Citations
31 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 107 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 31 references

HER-2 overexpression and doxorubicin in the adjuvant chemotherapy of resectable breast cancer

  • A. Moliterni, S. Menard, +5 authors G. Bonadonna
  • Proc. Am. Soc. Clin. Oncol.,
  • 2001

Superior outcomes with Herceptin (trastuzumab) in fluorescence in situ hybridization-selected patients

  • C. L. Vogel, M. Cobleigh, D. Tripathy, R. Mass, M. Murphy, S. J. Stewart
  • Proc. Am. Soc. Clin. Oncol.,
  • 2001
2 Excerpts

Amplification of topoisomerase II is a strong predictor of response to epirubicin-based chemotherapy in HER-2/neu positive metastatic breast cancer

  • J. J. Isola, M. Tanner, K. Holli, H. Joensuu
  • Breast Cancer Res. Treat.,
  • 2000
1 Excerpt

Similar Papers

Loading similar papers…